Who are dl-Methylphenidate plus Cannabidiol's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/dl-methylphenidate-plus-cannabidiol.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

dl-Methylphenidate plus Cannabidiol — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

dl-Methylphenidate plus Cannabidiol (dl-Methylphenidate plus Cannabidiol) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination therapy: sympathomimetic amine plus phytocannabinoid. Area: Psychiatry/Neurology.

marketed Combination therapy: sympathomimetic amine plus phytocannabinoid Dopamine transporter, norepinephrine transporter (methylphenidate); CB1/CB2 receptors, 5-HT1A, TRPV1 (cannabidiol) Psychiatry/Neurology Small molecule Live · refreshed every 30 min

Target snapshot

dl-Methylphenidate plus Cannabidiol (dl-Methylphenidate plus Cannabidiol) — University of Florida. dl-Methylphenidate increases dopamine and norepinephrine availability in the central nervous system, while cannabidiol modulates endocannabinoid signaling and has anti-inflammatory properties.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
dl-Methylphenidate plus Cannabidiol TARGET	dl-Methylphenidate plus Cannabidiol	University of Florida	marketed	Combination therapy: sympathomimetic amine plus phytocannabinoid	Dopamine transporter, norepinephrine transporter (methylphenidate); CB1/CB2 receptors, 5-HT1A, TRPV1 (cannabidiol)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination therapy: sympathomimetic amine plus phytocannabinoid class)

University of Florida · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). dl-Methylphenidate plus Cannabidiol — Competitive Intelligence Brief. https://druglandscape.com/ci/dl-methylphenidate-plus-cannabidiol. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing